In our study, this adverse effect was diagnosed in one patient, hypopituitarism was found in the thyroid, cortico-, growth hormone and gonadotropic lines with mild hyperprolactinemia with the onset of symptoms after 11 months of treatment [31]. Here, GH1 is linked to hyperprolactinemia.